SecBot SecBot

MOLN

MOLECULAR PARTNERS AG
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. V8· CIK 0001745114 Biotech & Drug Discovery
$3.81 +0.22 (+6.13%)
Oct 27 4:00 PM ET · prev $3.59
Market cap
$137.7M
Micro cap
Median target
🔒 Subscribers only
1 year
+1.6%
from $3.75 · Oct 28
30 days
−1.3%
from $3.86
52-week range
$3.56–5.13
−26% from high · low Oct 16
Avg volume 20D
2.0K
Oct 9 spike 5.7K
Short interest
🔒 Subscribers only
New fund stakes
0
Q4 2025 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest NEUTRAL Molecular Partners AG reported H1 2026 financial results, showing a net loss of CHF 26.7 million (improved…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q4 2025: 0 added (0 new), 1 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.340 → −$0.340 over 90 days.

  • TrendDOWNTREND

    6% below its 50-day average.

Who's buying

13F· Q4 2025
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT349$1.5K
UBS Group AGTRIM5,339$19.8K
UBS Group AGADD10,199$39.0K
UBS Group AGADD6,872$32.6K
MORGAN STANLEYTRIM367$1.7K
MORGAN STANLEYADD500$2.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Apr 22, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 16, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jan 27, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Dec 8, 2025JP Morgan
MAINTAIN
MAINTAINNeutral
Sep 3, 2025JP Morgan
MAINTAIN
MAINTAINNeutral
Mar 11, 2025LifeSci Capital
INITIATE
INITIATEOutperform

Earnings setup

Estimates
−$0.34
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.34-$0.34–-$0.34+4.2%$0.00
Next Q-$0.22-$0.22–-$0.22+38.9%$0.00
Current FY-$1.11-$1.46–-$0.65+4.6%$5.6M
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 18, 2026
Trading halt
Halt Resumed: MOLN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-18T16:33:57.000Z | Resumed 2026-09-18T16:43:57.000Z
Sep 18, 2026
Trading halt
Trading Halt: MOLN — LUDP (Volatility Trading Pause)
Molecular Partners AG ADS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 25, 2026
Press release
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG…
Jul 16, 2026
FDA
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners…
Jul 15, 2026
Press release
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a…

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Sep 18, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 Trading halt
Halt Resumed: MOLN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-18T16:33:57.000Z | Resumed 2026-09-18T16:43:57.000Z
Aug 25, 2026 SEC
Molecular Partners AG reported H1 2026 financial results, showing a net loss of CHF 26.7 million (improved from CHF…
6-K — Impact 4/10
Jul 20, 2026 SEC
Molecular Partners announced dosing of first patients in the Phase 2 TACTIC trial of MP0317 for first-line…
6-K — Impact 3/10
Jul 16, 2026 Press
Molecular Partners announced dosing of first patients in a Phase 2 proof-of-concept study (TACTIC) of MP0317 combined…
Impact 4/10
Jul 6, 2026 Press
Molecular Partners provided a pipeline update for its Radio-DARPin therapeutics, confirming ongoing Phase 1/2a dosing…
Impact 3/10
Jul 2, 2026 SEC
Molecular Partners announced the first patients have been dosed in a Phase 1/2a trial of MP0712, a DLL3-targeting…
6-K — Impact 5/10
Dec 31, 2025 Inst.
UBS Group AG — NEAR_EXIT
349 shares ($1.5K)
Sep 30, 2025 Inst.
UBS Group AG — TRIM
5,339 shares ($19.8K)

SecBot reports

6 filings · 5 press releases · 0 bullish · 0 bearish · 6 neutral
All MOLN filing & press-release reports (11)